Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine.

COVID-19 Roche Anti-SARS-CoV-2-S immune response mRNA vaccine serological test vaccination

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
19 Nov 2021
Historique:
received: 08 10 2021
revised: 05 11 2021
accepted: 17 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

Studies reporting the long-term humoral response after receiving the BNT162b2 COVID-19 vaccine are important to drive future vaccination strategies. Yet, available literature is scarce. Covidiagnostix is a multicenter study designed to assess the antibody response in >1000 healthcare professionals (HCPs) who received the BNT162b2 vaccine. Serum was tested at time-0 (T Six months post-vaccination HCPs showed an antibody titer decrease of approximately 70%, yet, the titer was still one order of magnitude higher than that of seropositive individuals before vaccination. We identified 12 post-vaccination infected HCPs. None showed severe symptoms. Interestingly, most of them showed titers at T Vaccination induces a humoral response which is well detectable even six months post-vaccination. Vaccination prevents severe COVID-19 cases, yet post-vaccination infection is possible even in the presence of a high anti-S serum antibody titer.

Sections du résumé

BACKGROUND BACKGROUND
Studies reporting the long-term humoral response after receiving the BNT162b2 COVID-19 vaccine are important to drive future vaccination strategies. Yet, available literature is scarce. Covidiagnostix is a multicenter study designed to assess the antibody response in >1000 healthcare professionals (HCPs) who received the BNT162b2 vaccine.
METHODS METHODS
Serum was tested at time-0 (T
RESULTS RESULTS
Six months post-vaccination HCPs showed an antibody titer decrease of approximately 70%, yet, the titer was still one order of magnitude higher than that of seropositive individuals before vaccination. We identified 12 post-vaccination infected HCPs. None showed severe symptoms. Interestingly, most of them showed titers at T
CONCLUSION CONCLUSIONS
Vaccination induces a humoral response which is well detectable even six months post-vaccination. Vaccination prevents severe COVID-19 cases, yet post-vaccination infection is possible even in the presence of a high anti-S serum antibody titer.

Identifiants

pubmed: 34835288
pii: vaccines9111357
doi: 10.3390/vaccines9111357
pmc: PMC8620373
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministero della Salute
ID : COVID-2020-12371619

Références

Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Vaccines (Basel). 2021 May 18;9(5):
pubmed: 34070196
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
J Med Virol. 2021 Apr;93(4):2160-2167
pubmed: 33064340
Vaccines (Basel). 2021 Aug 16;9(8):
pubmed: 34452038
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Lancet. 2021 Mar 27;397(10280):1178-1181
pubmed: 33640037
Clin Chem Lab Med. 2021 Oct 07;59(12):2019-2026
pubmed: 34614550
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Clin Chem. 2020 Nov 1;66(11):1405-1413
pubmed: 32777031
Vaccine. 2021 Jul 13;39(31):4256-4260
pubmed: 34147292
Semin Immunol. 2018 Dec;40:83-94
pubmed: 30501873
Emerg Microbes Infect. 2021 Dec;10(1):1495-1498
pubmed: 34232116
Int J Technol Assess Health Care. 2021 Sep 22;37(1):e87
pubmed: 34548114
Int J Infect Dis. 2021 Feb;103:590-596
pubmed: 33310108
N Engl J Med. 2021 Mar 8;384(15):1466-1468
pubmed: 33684280
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Hum Vaccin Immunother. 2016;12(1):239-43
pubmed: 26836329
Viruses. 2021 Jul 31;13(8):
pubmed: 34452380
Clin Chem. 2020 Aug 1;66(8):1104-1106
pubmed: 32484887
Clin Chim Acta. 2021 Aug;519:60-63
pubmed: 33857476
Forensic Sci Int. 2018 Jul;288:211-217
pubmed: 29775921
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Stat Methods Med Res. 2017 Jun;26(3):1373-1388
pubmed: 25847911
Clin Chim Acta. 2021 Nov;522:144-151
pubmed: 34425105
Clin Chem Lab Med. 2020 Jun 25;58(7):1095-1099
pubmed: 32301746

Auteurs

Davide Ferrari (D)

Scienze Chimiche della Vita e della Sostenibilità Ambientale (CVSA) Department, University of Parma, 43121 Parma, Italy.

Nicola Clementi (N)

Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy.
IRCCS Ospedale San Raffaele, Laboratory Medicine Service, 20158 Milan, Italy.

Elena Criscuolo (E)

Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy.

Alessandro Ambrosi (A)

Surgery and Medicne Depertment, University Vita-Salute San Raffaele, 20158 Milan, Italy.

Francesca Corea (F)

IRCCS Ospedale San Raffaele, Laboratory Medicine Service, 20158 Milan, Italy.

Chiara Di Resta (C)

IRCCS Ospedale San Raffaele, Laboratory Medicine Service, 20158 Milan, Italy.

Rossella Tomaiuolo (R)

Surgery and Medicne Depertment, University Vita-Salute San Raffaele, 20158 Milan, Italy.

Nicasio Mancini (N)

Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy.
IRCCS Ospedale San Raffaele, Laboratory Medicine Service, 20158 Milan, Italy.

Massimo Locatelli (M)

IRCCS Ospedale San Raffaele, Laboratory Medicine Service, 20158 Milan, Italy.

Mario Plebani (M)

Department of Laboratory Medicine, Padua University School of Medicine, 35100 Padua, Italy.

Giuseppe Banfi (G)

Surgery and Medicne Depertment, University Vita-Salute San Raffaele, 20158 Milan, Italy.
Laboratory of Clinical Chemistry and Microbiology, IRCCS Orthopedic Institute Galeazzi, 20161 Milan, Italy.

Classifications MeSH